Schedule 13G ownership disclosure

Protalix BioTherapeutics Inc

Security class unavailable · CUSIP: 74365A309

Event date: 2020-03-18

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
3,288,091
Percent of class
9.9900%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-20-038290
Form type
SC 13G
Filer
Dexcel Pharma Technologies Ltd.
CIK
CIK 1720007
Filed
Mar 25, 2020
Reporting period
Mar 18, 2020
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub